Christopher R. Fenimore - 03 Jan 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Signature
/s/**Christopher R. Fenimore
Issuer symbol
REGN
Transactions as of
03 Jan 2024
Transactions value $
-$2,076,548
Form type
4
Filing time
04 Jan 2024, 16:22:04 UTC
Previous filing
29 Dec 2023
Next filing
25 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $2.78M +5K +34.79% $555.67 19.4K 03 Jan 2024 Direct
transaction REGN Common Stock Tax liability -$3.69M -4.04K -20.87% $912.30 15.3K 03 Jan 2024 Direct
transaction REGN Common Stock Options Exercise $2M +5K +32.62% $399.66 20.3K 03 Jan 2024 Direct
transaction REGN Common Stock Tax liability -$3.16M -3.47K -17.06% $912.30 16.9K 03 Jan 2024 Direct
holding REGN Common Stock 1.47K 03 Jan 2024 2021 GRAT
holding REGN Common Stock 4.27K 03 Jan 2024 2022 GRAT
holding REGN Common Stock 1.5K 03 Jan 2024 By 401(k) Plan
holding REGN Common Stock 1.9K 03 Jan 2024 By Trust F1
holding REGN Common Stock 461 03 Jan 2024 by Trust for Daugh
holding REGN Common Stock 460 03 Jan 2024 by Trust for Son

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -5K -50% $0.00 5K 03 Jan 2024 Common Stock 5K $399.66 Direct F2
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -5K -50% $0.00 5K 03 Jan 2024 Common Stock 5K $555.67 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.